RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates

Company Performance - RenovoRx, Inc. reported a quarterly loss of $0.08 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.10 per share a year ago [1] - The company posted revenues of $0.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 22.32%, and showing a significant increase from zero revenues a year ago [2] - Over the last four quarters, RenovoRx has surpassed consensus EPS estimates two times [1] Stock Performance - RenovoRx shares have declined approximately 5.4% since the beginning of the year, while the S&P 500 has gained 10% [3] - The current Zacks Rank for RenovoRx is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $0.44 million, and for the current fiscal year, it is -$0.32 on revenues of $1.61 million [7] - The trend of estimate revisions for RenovoRx was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - RenovoRx operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 41% of over 250 Zacks industries [8] - Research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]